CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?

Lancet Oncol. 2019 Nov;20(11):1479-1481. doi: 10.1016/S1470-2045(19)30627-8. Epub 2019 Sep 28.

Authors

Shom Goel¹, Sara M Tolaney²

Affiliations

¹ Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: sara_tolaney@dfci.harvard.edu.

PMID: 31575504
DOI: 10.1016/S1470-2045(19)30627-8

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms*
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Humans
Protein Kinase Inhibitors
Triple Negative Breast Neoplasms*

Substances

Protein Kinase Inhibitors
CDK4 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6